Full Press Release Details
Eupraxia Pharmaceuticals to Present
at the H.C. Wainwright 26th Annual Global Investment Conference
Victoria, B.C. - September 4, 2024
- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology
company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need,
today announced that the Company will be presenting at the upcoming H.C. Wainwright 26th Annual Global Investment Conference being held
in New York, NY from September 9-11, 2024.
Presentation Details:
The Company's presentation is at 8:00 a.m. ET on Monday, September
9, 2024. Eupraxia invites all interested parties to view the presentation by clicking on the following link:
A webcast of the presentation will also
be available on the Events and Presentations page of the Company's website here.
About Eupraxia Pharmaceuticals
Eupraxia is a clinical-stage biotechnology
company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas
with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver
targeted, long-lasting activity with fewer side effects. DiffuSphere , a proprietary, polymer-based micro-sphere technology, is
designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic
(PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery
Eupraxia's EP-104GI is currently in
a Phase 1b/2a trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis ("EoE"). EP-104GI is administered as
an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently
completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to osteoarthritis of the knee. The trial
met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage
long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each
designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the
Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements and
This news release includes forward-looking statements and forward-looking
information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by
the use of words such as "plans", "is expected", "expects", "suggests", "scheduled",
"intends", "contemplates", "anticipates", "believes", "proposes", "potential"
or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results
"may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking
statements in this news release include statements regarding the details of the Company's presentation at the upcoming H.C. Wainwright
26th Annual Global Investment Conference; the Company's product candidates, including their expected benefits to patients with
respect to safety, efficacy, duration and tolerability; the results gathered from studies and trials of Eupraxia's product candidates;
the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's products;
and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and
are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially
as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability
to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability
to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and
information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release
may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting
Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel
technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product
candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current
license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for
its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to
obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's
clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development;
the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely
relies on third parties to provide supplies and inputs required for its products and services; the Company relies on external contract
research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its
business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will
be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory
approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement
of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence
and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public
filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov).
Although Eupraxia has attempted to identify
important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements
and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.
No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements
and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any
forward-looking statement or information, whether as a result of new information, future events or otherwise.
For investor and media inquiries, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
Adam Peeler, on behalf of:
Eupraxia Pharmaceuticals Inc.
SOURCE Eupraxia Pharmaceuticals Inc.